tiprankstipranks
Trending News
More News >
InflaRx NV (IFRX)
NASDAQ:IFRX
Advertisement

InflaRx (IFRX) AI Stock Analysis

Compare
712 Followers

Top Page

IFRX

InflaRx

(NASDAQ:IFRX)

Rating:42Neutral
Price Target:
$1.00
▲(17.65%Upside)
InflaRx's overall stock score reflects significant financial challenges, with ongoing losses and negative cash flows being the primary concerns. Technical analysis provides a neutral outlook, while poor valuation metrics add further downside risk. The absence of earnings call data and corporate events does not alter the fundamentally weak position.
Positive Factors
Commercial Opportunities
Both CSU and HS are meaningful commercial opportunities.
Drug Development
INF904 is a potentially better C5aR inhibitor than FDA-approved Tavneos, suggesting an improved design based on available PK/PD data.
Financial Performance
The company's cash runway guidance could get extended, with cash, cash equivalents, and marketable securities reported at €65.7M.
Negative Factors
Clinical Trial Challenges
The Independent Data Monitoring Committee recommended the Phase 3 trial evaluating vilobelimab in PG be stopped due to lack of observed treatment effect.
Disappointment in Drug Development
The failure is a large disappointment for the company and patients, especially considering the paucity of other assets in development for PG.

InflaRx (IFRX) vs. SPDR S&P 500 ETF (SPY)

InflaRx Business Overview & Revenue Model

Company DescriptionInflaRx (IFRX) is a clinical-stage biopharmaceutical company based in Germany, focused on discovering and developing anti-inflammatory therapeutics by targeting the complement system. The company's lead product candidate, vilobelimab, is a monoclonal antibody designed to inhibit the activity of C5a, a protein involved in the inflammatory response. InflaRx primarily operates within the biotechnology and pharmaceuticals sectors, with a focus on addressing severe and life-threatening inflammatory diseases.
How the Company Makes MoneyInflaRx makes money primarily through the development and potential commercialization of its pipeline of therapeutic candidates targeting the complement system. Revenue streams include potential partnerships with larger pharmaceutical companies for co-development and commercialization, as well as licensing agreements that can provide upfront payments, milestone payments, and royalties on sales. Additionally, as InflaRx progresses its drug candidates through clinical trials and towards potential regulatory approval, the company may receive funding through grants or investment from private and public sources to support its research and development activities.

InflaRx Financial Statement Overview

Summary
InflaRx's financial performance is weak, highlighted by consistent negative cash flow and operating losses, leading to a score at the lower end of the scale. The balance sheet shows limited leverage but negative returns on equity, indicating significant challenges in profitability and cash flow management.
Income Statement
35
Negative
InflaRx's income statement shows significant challenges in profitability and revenue growth. The company has been operating at a loss with negative net income and gross profit margins. Although total revenue increased from 2023 to 2024, the net profit margin remains negative, reflecting continued financial strain.
Balance Sheet
40
Negative
The balance sheet highlights high equity levels relative to debt, but the company has been operating with net debt positions, suggesting better liquidity management. However, the return on equity is negative due to persistent net losses, pointing to concerns in generating returns for shareholders.
Cash Flow
30
Negative
InflaRx's cash flow statement indicates consistent negative operating cash flow and free cash flow, suggesting ongoing cash burn issues. The free cash flow to net income ratio is poor, pointing to challenges in converting earnings into cash.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue165.79K63.09K0.000.000.00
Gross Profit-3.15M-469.17K-585.85K-696.14K-664.03K
EBITDA-45.55M-42.06M-31.29M-46.90M-32.47M
Net Income-46.06M-42.67M-27.04M-45.65M-34.01M
Balance Sheet
Total Assets76.02M120.21M102.40M125.14M88.22M
Cash, Cash Equivalents and Short-Term Investments52.84M90.27M81.81M83.41M81.13M
Total Debt805.09K1.12M1.36M1.43M559.04K
Total Liabilities14.60M17.63M14.05M19.86M10.35M
Stockholders Equity61.42M102.58M88.35M105.28M77.86M
Cash Flow
Free Cash Flow-48.60M-37.89M-33.91M-39.97M-36.62M
Operating Cash Flow-48.56M-37.81M-33.74M-39.94M-36.53M
Investing Cash Flow52.36M-17.70M19.36M-25.95M21.36M
Financing Cash Flow386.45K52.99M1.94M61.58M9.17M

InflaRx Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.85
Price Trends
50DMA
1.02
Negative
100DMA
1.14
Negative
200DMA
1.60
Negative
Market Momentum
MACD
-0.03
Negative
RSI
45.45
Neutral
STOCH
40.93
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IFRX, the sentiment is Negative. The current price of 0.85 is above the 20-day moving average (MA) of 0.84, below the 50-day MA of 1.02, and below the 200-day MA of 1.60, indicating a neutral trend. The MACD of -0.03 indicates Negative momentum. The RSI at 45.45 is Neutral, neither overbought nor oversold. The STOCH value of 40.93 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IFRX.

InflaRx Risk Analysis

InflaRx disclosed 82 risk factors in its most recent earnings report. InflaRx reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 3 New Risks
1.
Our success depends on our ability to obtain, maintain, protect, defend and enforce patent, trade secret and other intellectual property protection Q4, 2022
2.
Our manufacturing process is subject to quality control risks and related regulatory requirements Q4, 2022
3.
Failure to maintain compliance with FDA requirements and/or remain in alignment with FDA feedback may prevent or delay the development, marketing or manufacturing of vilobelimab for the treatment of critically ill COVID-19 patients and, potentially, of vilobelimab in ulcerative PG Q4, 2022

InflaRx Peers Comparison

Overall Rating
UnderperformOutperform
Sector (50)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
57
Neutral
$79.02M-46.28%-33.00%54.91%
50
Neutral
AU$2.62B3.32-57.47%2.40%36.73%13.67%
43
Neutral
$45.46M91.63%-55.47%24.92%
42
Neutral
$57.07M-62.38%178.84%-40.60%
39
Underperform
$149.31M-73.85%-40.59%
35
Underperform
$49.12M-101.34%21.40%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IFRX
InflaRx
0.85
-0.68
-44.44%
VTGN
VistaGen Therapeutics
2.71
-0.97
-26.36%
CLSD
Clearside Biomedical
0.54
-0.63
-53.85%
CABA
Cabaletta Bio
1.66
-5.53
-76.91%
JSPR
Jasper Therapeutics
3.13
-17.46
-84.80%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 10, 2025